thank stand welcome laboratory third quarter earn conference call time participant listen mode speaker presentation question answer session operator instruction please advise today conference record operator instruction would like turn conference speaker today vice president investor relation begin corporate vice president investor relation thank good morning welcome laboratory third quarter earn conference call webcast morning foster chairman president chief executive officer executive vice president chief financial officer comment result third quarter follow presentation respond question slide presentation associate today remark post investor relation section website criver webcast replay call available begin approximately hour call today also access investor relation website replay available next quarter conference call like remind safe harbor remark make future expectation plan prospect company constitute forward look statement private security litigation reform actual result differ materially indicate call primarily financial measure believe help investor gain meaningful understand core operate result guidance financial measure mean consider superior substitute result operation prepare accordance accordance regulation find comparable measure reconciliation investor relation section website turn call foster foster chairman chief executive officer president good morning strong third quarter result demonstrate effectiveness strategy progress make execution sustain strength industry fundamental anticipate third quarter revenue increase teen rate organically report teen earn share growth believe stronger company today ever unprecedented demand across business believe couple strength lead nonclinical portfolio enable achieve double digit organic revenue growth target longer term result continue invest people capacity accommodate grow client demand build scalable operate model enhance scientifically distinguish portfolio strengthen relationship client work devise outsource solution enable increase productivity speed market maintain focus nonclinical drug research manufacture solution strategically expand portfolio provide client critical capability require discover develop safely manufacture drug last month divest operation site total approximately million plus potential contingent payment additional million routinely evaluate strategic fundamental performance global infrastructure acquisition legacy site alike sell close operation meet business criterion underperform financially decision divest operation consistent evaluation process intend redeploy capital growth area business move third quarter highlight financial performance follow report revenue million third quarter increase last year organic revenue growth business segment contribute strong performance last year impact result modest basis point increase organic revenue growth client perspective biotech continue drive revenue growth global biopharmaceutical client also make solid contribution quarter third quarter report revenue growth affect million foreign exchange headwind compare prior outlook notwithstanding impact continue strong sustain client demand across business trend largely consistent first quarter year operate margin decrease basis point year year anticipate decline primarily drive comparison strong third quarter last year benefit control impact acquisition manufacture segment operate margin operate margin first nine month year squarely track achieve goal approximately represent basis point increase prior year also demonstrate commitment drive efficiency achieve longer term margin target earn share phonetic third quarter increase third quarter last year result favorable prior outlook large part lower expect rate provide additional detail rate shortly sustain strength demand environment revise financial guidance reflect three primary factor unfavorable movement foreign exchange lower rate divestiture report revenue growth lower approximately basis point midpoint range primarily reflect current rate impact divestiture narrow organic revenue growth outlook approximately basis point increase generate comparison last year impact normalize organic growth expect squarely double digit range year consistent target growth rate next year also narrow earn share guidance range represent year year growth please maintain growth within previous range even absorb impact divestiture like provide detail third quarter segment performance begin segment revenue third quarter million increase organic basis strength safety assessment include science bioanalytical service discovery service demand service price increase drive double digit organic growth segment trend expect continue next year biotech client leverage expertise rather invest internal capability global biopharmaceutical client choose partner efficient leverage flexible infrastructure instead maintain expand believe become principal partner choice biotech client size demand service high sustain level biotech fund enable client meaningfully invest early stage research accelerate pace internal capability type work perform meet client grow need focus business unmatched scientific expertise rapid turnaround time flexible creative solution ability accommodate increase complexity client research program safety assessment business continue perform third quarter book proposal volume continue track record level mention throughout year client choose book safety assessment study advance enhance ability start work soon molecule ready early book extend translate greater visibility stronger book business strong demand service require closely manage current workload staff capacity necessary resource manage continual shift client time line study protocol associate book work client focus business approach believe balance priority capability effectively make even indispensable research partner client large small also make progress goal continually improve connectivity client include digital enhancement strive take additional year client drug development time line discovery business strong year drive comprehensive portfolio oncology early discovery antibody discovery capability biotech client continue choose invest pipeline instead infrastructure utilize integrate service move program forward global biopharmaceutical company continue increase reliance outsource strategy discovery program prefer leverage edge discovery capability flexible solution create efficient model please work biotech global biopharma client partner discover develop bring critical therapy patient need support robust demand client continue strengthen portfolio expand scale science innovative technology combination internal investment strategic partnership strategy enable client remain scientific partner target identification file beyond solidify position lead nonclinical operate margin decrease basis point third quarter increase sequentially year year decline foreign exchange reduce operate margin approximately basis point discovery milestone payment contribute basis point last year operate margin revenue million increase organic basis third quarter approximately basis point increase attributable comparison last year relate revenue impact performance largely reflect trend experience year robust demand research model particularly broad base growth across research model service partially offset continue headwind cell supply business research model business continue experience strong double digit growth solid performance north believe correlate increase level nonclinical research activity conduct biopharmaceutical academic client believe global focus scientific innovation sustainable continue drive client demand however biopharmaceutical market participate trend result choose divest operation opportunistic sale laboratory establish license agreement produce distribute model research model service perform benefit strong outsource demand client seek greater flexibility efficiency gain manage proprietary model greater complexity scientific research proprietary model client create reinforce value proposition business client need greater flexibility efficiency also drive demand insourcing solution business particularly initiative provide small large biopharmaceutical client turnkey research capacity site last month announce expansion footprint continue expand region include south south provide flexible capacity solution client globally utilize also provide client collaborative opportunity seamlessly access service enhance speed efficiency research program cell supply business consist continue affect limitation donor availability fully recover last year relate restriction implement several improvement initiative include expansion donor capacity across multiple site productivity initiative enhance digital engagement donor anticipate revenue improve come quarter robust demand cell therapy market sector remain firmly intact operate margin decrease basis point year year primarily cell supply business like many business cell supplier leverage sale volume expect profitability meaningfully improve donor availability growth rate rebound revenue manufacture segment million increase organic basis third quarter last year increase primarily drive continue strong double digit revenue growth biologics test solution microbial solution business approximately basis point attributable comparison last year relate revenue impact microbial solution growth rate third quarter remain reflect strong demand across portfolio critical quality control test solution please strength underlie demand endotoxin test system cartridge perform mandate release test injectable drug medical device advantage comprehensive portfolio continue resonate client believe ability provide total microbial test solution enable microbial solution deliver least double digit organic revenue growth year beyond biologics test business report another exceptional quarter strong double digit revenue growth robust demand cell gene therapy test service continue primary growth driver vaccine traditional biologics also meaningful contributor believe cell gene therapy continue significant growth driver longer term support growth target business strength demand service necessitate continue build extensive portfolio manufacture service ensure available capacity accommodate client demand third quarter mark first full quarter part anticipate acquire large relate project complete second quarter actively project place continue make great progress integration believe cell gene therapy business highly complementary biologics business portfolio whole also believe comprehensive cell gene therapy portfolio span major platform gene modify cell therapy viral vector plasmid production goal enable client conduct analytical test process development manufacture advance drug modality scientific partner allow achieve goal drive greater efficiency accelerate speed market mention earlier decision divest site base several factor first capability include plasmid already duplicate site second determine would advantageous invest expand capacity centrally locate proximate client finally smallest least profitable site divestiture reflect change client demand cell gene therapy sector firmly believe growth profile business remain longer term manufacture segment third quarter operate margin decline basis point primary driver decline inclusion full quarter business profitable margin overall manufacture segment note last quarter continue expect full year manufacture margin slightly range reflect addition business however beyond expect headwind gradually dissipate drive efficiency significant growth anticipate generate greater economy scale optimize throughput site operate robust business environment excellent growth potential biotech fund continue track robust level sustain fund environment capital market biopharmaceutical industry biotech industry cash reserve enable accelerate pace scientific innovation client large small view partner choice concept nonclinical development safe manufacture life save therapeutic continue successfully execute strategy maintain enhance position lead nonclinical accommodate client growth need essential continue make investment scientific capability technology partnership internal development enhance digital enterprise provide real time access critical data internal client also expand capacity staff demand service current market environment outpace expectation hire ahead initial plan year accommodate growth hire talented people year support growth offset attrition plan hire additional people fourth quarter believe attract qualify employee mission critical work help client develop life save therapy distinguish company business like staff consistent challenge place disproportionate focus believe effectively manage staff level include increase continue thoughtful respect compensation head strive maintain reduce turnover remain competitive marketplace headwind help support robust client demand achieve double digit organic growth target expect focus intently strategy become trust scientific partner pharmaceutical biotechnology company academic institution government organization worldwide demonstrate value provide client believe trust work drug approve last three year believe steady focus strategy continue enhance portfolio enable continue achieve long term financial target deliver greater value shareholder conclusion like thank client shareholder support employee exceptional work commitment give additional detail third quarter result update guidance corporate executive vice president chief financial good morning begin remind speak primarily result exclude amortization transaction relate charge relate primarily global efficiency initiative venture capital strategic investment performance certain item many comment also refer organic revenue growth exclude impact acquisition divestiture foreign currency translation please strong result third quarter include organic revenue growth increase earn share operate margin third quarter lower prior year anticipate represent basis point sequential increase line full year target approximately addition control last year acquisition year mention third quarter operate margin also lower last year robust level foreign exchange headwind last year discovery milestone payment although inflation supply chain pressure make headline recently believe effectively manage tighter labor market supply chain higher area reflect update guidance lower unallocated corporate contribute third quarter operate margin come revenue million compare revenue last year corporate nonlinear fluctuate quarter quarter several factor include health fringe relate performance base compensation despite third quarter favorability continue expect unallocated corporate range percentage revenue full year third quarter rate represent basis point decrease third quarter last year lower rate primarily factor discrete benefit associate credit favorable excess benefit relate stock base compensation associate higher stock price benefit also result reduction full year rate range prior outlook total adjust interest expense third quarter million increase million year year reflect higher debt balance fund acquisition essentially flat sequentially third quarter outstanding debt balance billion represent gross leverage ratio leverage ratio full year expect total adjust interest expense slightly lower prior outlook range million million reflect debt repayment continue variable interest rate free cash flow million third quarter represent decrease million period last year lower free cash flow primarily higher capital expenditure increase nearly million million reason increase capital expenditure continue invest capacity addition growth project meet client demand last year level still constrain relate project rate year free cash flow capex guidance remain unchanged approximately million million respectively capex expect total total revenue robust demand environment exceed expectation year expect continue across portfolio believe capex total revenue next year continue capacity support growth particularly legacy business include safety assessment respect guidance update full year revenue growth outlook range report basis reflect impact divestiture foreign exchange organic revenue growth foreign exchange expect benefit previously anticipate strengthen dollar last three month particularly compare pound euro expect basis point benefit year compare prior outlook approximately basis point mention strength dollar result headwind reduce third quarter report revenue approximately million compare prior outlook narrow earn share guidance range primarily lower rate outlook partially offset divestiture please keep mind divestiture expect reduce revenue nearly million earn share fourth quarter reflect full year financial guidance segment update outlook continue reflect sustain healthy business environment organic revenue growth outlook narrow within previous range maintain segment growth expectation include organic revenue growth high teen segment double digit segment high teen manufacture segment report basis moderate segment outlook reflect update rate divestiture expect revenue growth segment high teen range manufacture range unchanged teen regard operate margin segment outlook remain effectively unchanged prior outlook detail summary update financial guidance full year find slide quarter remain year fourth quarter outlook effectively embed guidance full year divestiture affect year year comparison fourth quarter year year basis expect organic revenue growth high single digit report revenue growth double digit range normalize impact expect organic revenue growth full year squarely double digit range also consistent growth shall next year earn share expect flat single digit increase fourth quarter compare last year level fourth quarter rate expect return range along divestiture meaningfully constrain earn share growth rate would like provide model comment regard next year week fourth quarter periodically require true fiscal year calendar year week historically characterize partial week revenue since occur holiday full week conclude turn page next year intend finish fourth quarter strong note achieve update financial guidance year expect performance demonstrate progress make investment necessary achieve financial target provide investor include double digit organic revenue growth operate margin approximately earn share growth faster rate revenue thank corporate vice president investor conclude comment operator take question